drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous BCMA-directed chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are gene-modified to express a CAR targeting BCMA (TNFRSF17) and, upon binding, kill BCMA-positive plasma cells to reduce pathogenic autoantibodies in SLE. Administered by IV infusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a BCMA (TNFRSF17)-targeting chimeric antigen receptor. Upon engaging BCMA on plasma cells/late B cells, the CAR T cells become activated and kill these BCMA-positive cells, depleting autoantibody-secreting plasma cells and reducing pathogenic autoantibodies in SLE.
drug_name
SYS6020
nct_id_drug_ref
NCT06694298